In cancer, these DTPs were first described in 2010 by Sharma et al. in the EGFR-mutant NSCLC PC9 cell line, where authors observed a small fraction of largely non-proliferating cells that resisted to EGFR-TKI treatments at doses 100 times higher than the IC50 value [47]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.